4-(4-Methoxyphenyl)-5-(4-methylthiazol-2-yl)-2H-[1,2,3]triazole | 529512-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-Methoxyphenyl)-5-(4-methylthiazol-2-yl)-2H-[1,2,3]triazole
• 英文别名: 2-[5-(4-methoxyphenyl)-2H-triazol-4-yl]-4-methyl-1,3-thiazole
• CAS: 529512-87-6
• 化学式: C₁₃H₁₂N₄OS
• 分子量: 272.33
• InChiKey: PKVPOTOGYBXPBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  91.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(4-Methoxyphenylethynyl)-4-methylthiazole 、 Trimethylsilylacetylene azide 在 氩 、 乙酸乙酯 、 水 、 Brine 、 magnesium sulfate 、 petroleum ether 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.08h， 以ethyl acetate to yield a yellow solid product (100 mg, 32%)的产率得到4-(4-Methoxyphenyl)-5-(4-methylthiazol-2-yl)-2H-[1,2,3]triazole
  参考文献：
  名称：

  Thiazolyl substituted triazoles as alk5 inhibitors

  摘要：

  公式（I）中的噻唑基取代的三唑化合物1，其中R1是萘基或苯基，可选地取代一种或多种取代基，所选取代基包括卤素，—O—C1-6烷基，—S—C1-6烷基，C1-6烷基，C1-6卤代烷基，—O—（CH2）n—Ph，—S—（CH2）n—Ph，氰基，苯基和CO2R，其中R是氢或C1-6烷基，n为0，1，2或3；或者R1是与5-7个成员的芳香或非芳香环状环融合的苯基，所述环状环可选地包含高达三个杂原子，独立选择自N，O和S，其中N可以进一步选自C1-6烷基取代，环状环可以可选地被═O取代；或者R1是与5-7个成员的芳香或非芳香环融合的吡啶基，所述环状环可选地包含高达三个杂原子，独立选择自N，O和S，其中N可以进一步选自C1-6烷基取代，环状环可以可选地被═O取代；R2是H，C1-6烷基，C1-6烷氧基，苯基，NH（CH2）n—Ph，NH—C1-6烷基，卤素，CN，NO2，CONHR和SO2NHR；X1、X2和X3中的两个是N，另一个是NR3，其中R3是氢，C1-6烷基，C3-7环烷基，—（CH2）p—CN，—（CH2）p—CO2H，—（CH2）p—CONHR4R5，—（CH）pCOR4，—（CH2）q（OR6）2，—（CH2）pOR4，—（CH2）qCH═CH—CN，—（CH2）q—CH═CH—CO2H，—（CH2）p—CH═CH—CONHR4R5，—（CH2）pNHCOR7或—（CH2）pNR8R9；R4和R5独立选择自氢或C1-6烷基；R6是C1-6烷基；R7是C1-7烷基，或可选地取代芳基，杂芳基，芳基C1-6烷基或杂芳基C1-6烷基；R8和R9独立选择自氢，C1-6烷基，芳基和芳基C1-6烷基；p为0-4；q为1-4及其盐和溶剂化合物，以及它们的制备方法，包含它们的药物组合物以及它们在医学上的使用。

  公开号：

  US20040266842A1

文献信息

• THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1444227A1

  公开（公告）日：2004-08-11
• [EN] THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS<br/>[FR] TRIAZOLES A SUBSTITUANT THIAZOLYLE UTILISES COMME INHIBITEURS DE ALK5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003042207A1

  公开（公告）日：2003-05-22

  Thiazolyl substituted triazoles of formula (I) wherein R1 is naphthyl or phenyl optionally substituted with one or more substituents selected from halo, -O-C1-6-alkyl, -S-C1-6alkyl, C1-6alkyl, C1-6haloalkyl, -O-(CH2) n-Ph, -S-(CH2) n-Ph, cyano, phenyl, and CO2R, wherein R is hydrogen or C1-6alkyl, and n is 0, 1, 2 or 3; or R1 is phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C1-6alkyl, and wherein the cyclic ring may be optionally substituted by =O; or R1 is pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C1-6alkyl, and wherein the cyclic ring may be optionally substituted by =O; R2 is H, C1-6alkyl, C1-6alkoxy, phenyl, NH(CH2)n-Ph, NH-C1-6alkyl, halo, CN, NO2, CONHR and SO2NHR; two of X1, X2 and X3 are N and the other is NR3 wherein R3 is hydrogen, C1-6 alkyl, C3-7cycloalkyl, -(CH2)p-CN, -(CH2)p-CO2H, -(CH2)p-CONHR4R5, -(CH2)pCOR4, -(CH2)q(OR5)2, -(CH2)pOR4, -(CH2)q-CH=CH-CN, -(CH2) q-CH=CH-CO2H, -(CH2)P-CH=CH-CONHR4R5, -(CH2)PNHCOR 7 or -(CH2)PNR8R9; R4 and R5 are independently hydrogen or C1-6alkyl; R6 is C1-6alkyl; R7 is C1-7alkyl, or optionally substituted aryl, heteroaryl, arylC1-6alkyl or heteroaryl1-6alkyl; R8 and R9 are independently selected from hydrogen, C1-6alkyl, aryl and arylC1-6alkyl; p is 0-4; and q is 1-4and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.